In the clinical trial, among 39 patients with EGFR TKI‐refractory NSCLC, 33 patients with high CD70 expression had a higher risk of death (4.95‐fold) compared with the low CD70 group.[254]. This evidence concerns the gene CD70 and non-small cell lung carcinoma.